Abstract
Delivery to the lungs is an efficient way to deliver drugs directly to the site of action or to the blood circulation. Because of limitations of direct administration of free drugs, particulate drug delivery systems such as DPI formulations based on nanoparticles (NPs) have been of interest for pulmonary drug delivery. The prolonged residence of NPs in the lungs due to ability to escape from the clearance mechanisms such as mucociliary escalator, macrophage uptake (a size of 1–2 m is ideal for macrophage phagocytosis), and translocation to the systemic circulation is amongst the key advantages of NPs. By this approach, the controlled pulmonary delivery of drugs, peptides, proteins, genes, siRNA, and vaccines is possible. Both natural (albumin, gelatin, alginate, collagen, cyclodextrin, and chitosan) and synthetic (poly (lactide-co-glycolide) (PLGA), polyacrylates and polyanhydrides) polymers have been used in formulation of pulmonary nanovectors. As direct pulmonary administration of NPs is not feasible, by using the safe excipients, NPs could be converted to dry powder inhaler (DPI) formulations. These can provide a promising deposition and stability of NPs. In this article, the DPI formulations based on polymeric nanoparticles have been reviewed and categorized based on the polymer type used for preparation of NPs.
Keywords: Dry powder inhaler, pulmonary, lung, polymeric, nanoparticles, drug delivery.
Current Pharmaceutical Design
Title:Dry Powder form of Polymeric Nanoparticles for Pulmonary Drug Delivery
Volume: 22 Issue: 17
Author(s): Farideh Shiehzadeh and Mohsen Tafaghodi
Affiliation:
Keywords: Dry powder inhaler, pulmonary, lung, polymeric, nanoparticles, drug delivery.
Abstract: Delivery to the lungs is an efficient way to deliver drugs directly to the site of action or to the blood circulation. Because of limitations of direct administration of free drugs, particulate drug delivery systems such as DPI formulations based on nanoparticles (NPs) have been of interest for pulmonary drug delivery. The prolonged residence of NPs in the lungs due to ability to escape from the clearance mechanisms such as mucociliary escalator, macrophage uptake (a size of 1–2 m is ideal for macrophage phagocytosis), and translocation to the systemic circulation is amongst the key advantages of NPs. By this approach, the controlled pulmonary delivery of drugs, peptides, proteins, genes, siRNA, and vaccines is possible. Both natural (albumin, gelatin, alginate, collagen, cyclodextrin, and chitosan) and synthetic (poly (lactide-co-glycolide) (PLGA), polyacrylates and polyanhydrides) polymers have been used in formulation of pulmonary nanovectors. As direct pulmonary administration of NPs is not feasible, by using the safe excipients, NPs could be converted to dry powder inhaler (DPI) formulations. These can provide a promising deposition and stability of NPs. In this article, the DPI formulations based on polymeric nanoparticles have been reviewed and categorized based on the polymer type used for preparation of NPs.
Export Options
About this article
Cite this article as:
Shiehzadeh Farideh and Tafaghodi Mohsen, Dry Powder form of Polymeric Nanoparticles for Pulmonary Drug Delivery, Current Pharmaceutical Design 2016; 22 (17) . https://dx.doi.org/10.2174/1381612822666160128150449
DOI https://dx.doi.org/10.2174/1381612822666160128150449 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Truncated Snail1 Transcription Factor Alters the Expression of Essential EMT Markers and Suppresses Tumor Cell Migration in a Human Lung Cancer Cell Line
Recent Patents on Anti-Cancer Drug Discovery Evaluation of In-Vitro Multidrug Resistance Reversal Activities of HZ08 analogues with Improved Soluble Property
Letters in Drug Design & Discovery Drug-Glycosidation and Drug Development
Mini-Reviews in Medicinal Chemistry Benzo[a]pyrene Toxicity and Inflammatory Disease
Current Rheumatology Reviews Cancer Microbiome; Opportunities and Challenges
Endocrine, Metabolic & Immune Disorders - Drug Targets RNA-Mediated Therapeutics: From Gene Inactivation to Clinical Application
Current Topics in Medicinal Chemistry <i>In Vitro</i> and <i>In Vivo</i> Evaluation of Novel DTX-Loaded Multifunctional Heparin-Based Polymeric Micelles Targeting Folate Receptors and Endosomes
Recent Patents on Anti-Cancer Drug Discovery Cannabinoid Receptor Type 2 Activation in Atherosclerosis and Acute Cardiovascular Diseases
Current Medicinal Chemistry Potential Application of Gene Therapy to X-Linked Agammaglobulinemia
Current Gene Therapy Camptothecins and Topoisomerase I; A Foot in the Door. Targeting the Genome Beyond Topoisomerase I with Camptothecins and Novel Anticancer Drugs; Importance of DNA Replication, Repair and Cell Cycle Checkpoints
Current Medicinal Chemistry - Anti-Cancer Agents Reversal of ABC Drug Transporter-Mediated Multidrug Resistance in Cancer Cells: Evaluation of Current Strategies
Current Molecular Pharmacology Minifish mtDNA has Abundance of Repeat Sequences and Inefficient Replication In Vitro
Current Molecular Medicine Flavonoids in Atherosclerosis: An Overview of Their Mechanisms of Action
Current Medicinal Chemistry Quality Assessment of Diagnostic Methods Employed for Suspected Lung Cancer
Current Respiratory Medicine Reviews Chemical Origins of Isoform Selectivity in Histone Deacetylase Inhibitors
Current Pharmaceutical Design COPD Evaluation: Beyond the Airway Obstruction, a Follow Up
Current Respiratory Medicine Reviews A Maximum Entropy Estimator for the Average Survival Time Differences between Two Groups
Clinical Cancer Drugs siRNA Delivery by Stimuli-Sensitive Nanocarriers
Current Pharmaceutical Design Natural Product Inhibitors of Hsp90: Potential Leads for Drug Discovery
Mini-Reviews in Medicinal Chemistry Deubiquitinating Enzymes as Promising Drug Targets for Infectious Diseases
Current Pharmaceutical Design